Immunology 2002 106 200–211




   Accumulation potent cd T-cell stimulator deletion lytB gene
                               Escherichia coli


   MATTHIAS EBERL,*" BORAN ALTINCICEK,{" ANN-KRISTIN KOLLAS,*" SILKE SANDERBRAND,{
    UTE BAHR,{ ARMIN REICHENBERG,{ EWALD BECK,* DONALD FOSTER,1 JOCHEN WIESNER,{
MARTIN HINTZ{ & HASSAN JOMAA{ *Biochemisches Institut, Justus-Liebig-Universita¨t Giessen, Giessen, Germany,
 {Jomaa Pharmaka GmbH, Giessen, Germany, {Instrumentelle Analytische Chemie, Johann Wolfgang Goethe-Universita¨t
      Frankfurt Main, Frankfurt, Germany 1Department Cytokine Biology, Zymogenetics , Seattle,
                                               Washington, USA




                                                            SUMMARY
                 Activation human Vc9/Vd2 T cells pathogens depends presence small
                 phosphorylated non-peptide compounds derived 2-C-methyl-D-erythritol
                 4-phosphate (MEP) pathway isoprenoid biosynthesis. demonstrate                  Escherichia coli mutants deficient lytB, essential gene MEP pathway, potent
                 Vc9/Vd2 T-cell activator accumulates factor approximately 150 compared wild-type
                 E. coli. compound responsible strong immunogenicity E. coli mutant                  subsequently characterized identified small pyrophosphorylated metabolite,                  molecular mass 262 Da, derived MEP pathway. Stimulation human peripheral
                 blood mononuclear cells (PBMC) extracts prepared lytB-deficient E. coli
                 mutant led upregulation T-cell activation markers surface Vc9/Vd2 T cells                  proliferation expansion Vc9/Vd2 T cells. response dependent                  costimulatory growth factors, interleukin  -2, 15 21. Significant levels                  interferon-c (IFN-c) tumour necrosis factor (TNF  secreted presence                  2 15, presence 21, demonstrating proliferating
                 phosphoantigen-reactive Vc9/Vd2 T cells necessarily produce proinflammatory
                 cytokines.




                                                                                             INTRODUCTION
                                                                          cd T cells play crucial role immune response
   Received 29 October 2001; revised 16 January 2002; accepted            microbial pathogens, capable 11 February 2002.
                                                                          establishing chronic debilitating diseases,    Abbreviations: DOXP, 1-deoxy-D-xylulose 5-phosphate; Dxr,              tuberculosis malaria.1,2 humans, activation Vc9/
1-deoxy-D-xylulose 5-phosphate reductoisomerase; ESI, electro-            Vd2 T cells pathogenic micro-organisms depends
spray ionization; FBPP, 3-formyl-1-butyl pyrophosphate;
                                                                          compounds derived 2-C-methyl-D-erythritol
HMB-PP, (E )-4-hydroxy-3-methyl 2-enyl pyrophosphate;
IFN-c, interferon-c;  interleukin; IPP, isopentenyl pyrophos-
                                                                          4-phosphate (MEP)1 pathway isoprenoid biosynthesis.3,4
phate; LMW, low molecular weight;  2-C-methyl-D-erythritol;            chloroplasts algae higher plants,
MEcPP, 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate; MEP,               pathway utilized bacteria,5,6 2-C-methyl-D-erythritol 4-phosphate; MS, mass spectrometry;               apicomplexan protozoa Plasmodium falciparum,7
TNF  tumour necrosis factor                                           apparently absent vertebrates.8–11      "M. Eberl, B. Altincicek -K. Kollas contributed equally         unconventional cd T-cell reactivity common metabolites work.                                                             ensures quick efficient immune response                                                                           broad range evolutionarily distant pathogens     Correspondence: Dr M. Eberl, Biochemisches Institut,
Klinikum der Justus-Liebig-Universita¨t Giessen, Friedrichstrasse         escape classical major histocompatibility
24, D-35392 Giessen, Germany. E-mail: matthias.eberl@biochemie.           complex-restricted mechanisms.12 isopentenyl pyro-
med.uni-giessen                                                        phosphate (IPP), precursor isoprenoids, 

                                                                    200                                  #   2002 Blackwell Science                                      potent cd T-cell activator DlytB E. coli                                     201

 ligand described Vc9/Vd2 T-cell receptor          isomerase (D-glyceraldehyde-3-phosphate-ketol-isomerase;
(TCR),13–15 natural amounts IPP bacteria           Sigma) 40 mg recombinant E. coli DOXP synthase.24 reach minimum required inducing T-cell              [2-14C]DOXP precipitated 100 mM BaCl2 activation.3 Fournie´ workers showed              80  ethanol, subsequently transformed mycobacterial molecule likely 3-formyl-1-butyl            [2-14C]MEP presence 25 mM NADPH (Sigma)
pyrophosphate (FBPP) approximately 1000-fold            using 300 mg recombinant E. coli DOXP reducto-
active IPP;16,17 structural similarity   isomerase (Dxr).7 Samples passed porous
IPP, FBPP suggested intermediate MEP        graphitized carbon column (Hypercarb; Thermo Hypersil,
pathway.17  terminal steps MEP               Runcorn, UK). Finally, [2-14C]MEP purified pathway remain elucidated, 2-C-methyl-D-       MonoQ column (Amersham Pharmacia, Freiburg,
erythritol 2,4-cyclopyrophosphate (MEcPP)        Germany), using 20 mM Tris–HCl, pH 8.0, rising
metabolite reaction sequence known far,           concentrations NaCl, Gynkotech HPLC device
evidence FBPP natural intermediate IPP             (Gynkotech, Germering, Germany). procedure
biosynthesis missing.18                                      yielded <1.6 mg [2-14C]MEP activity      recently, role genes dxr, gcpE lytB     <344 MBq/mmol (data shown). MEP pathway demonstrated 19–23 constructed Escherichia coli mutant strains
                                                                Metabolic 14C labelling metabolites derived utilizing exogenously provided mevalonate producing
                                                                MEP pathway
IPP, owing complementation plasmid                                                                 fresh overnight culture DgcpE DlytB mutants,
provides yeast enzymes classical mevalonate
                                                                respectively, diluted 1 : 100 2 ml medium sup-
pathway isoprenoid synthesis. Consequently, mutants
                                                                plemented 100 mM mevalonate 100 mg/ml
deficient genes dxr, gcpE lytB, respectively,                                                                 ampicillin. MEP taken E. coli,
viable culture medium supplemented                                                                 [2-14C]MEP treated 2 U shrimp alkaline phos-
mevalonate.20,21 Low-molecular-weight (LMW) extracts
                                                                phatase (Roche Diagnostics, Mannheim, Germany) 37u
prepared Ddxr DgcpE mutants signifi-
                                                                30 min, resulting product, [2-14C]-methyl-D-
cantly reduced capacity stimulate Vc9/Vd2 T cells,
                                                                erythritol ([2-14C , added cultures compared parent E. coli strain,4 proving                                                                 concentration 50 mM (corresponding c. 17.1 kBq/ml).
importance MEP pathway biosynthesis                                                                 Fosmidomycin, potent inhibitor Dxr enzyme,7 cd T-cell activator. striking contrast,                                                                 used 100 mM block endogenous biosynthesis DlytB bacteria, Vc9/Vd2 T cell-stimulating molecule
                                                                MEP consequently ensure optimum incorpora- greatly accumulated.
                                                                tion [2-14C metabolites produced MEP
                                                                pathway. incubation 37u 6 hr, bacterial cells
                                                                pelleted, resuspended 200 ml 5 mM Tris–HCl,
              MATERIALS METHODS                             pH 7.5, lysed repeated freeze–thaw cycles Bacteria plasmids                                           presence 2 mg lysozyme (Merck). Cell debris Bacterial strains E. coli DgcpE E. coli DlytB          pelleted supernatants loaded Microcon
precise frame deletions gcpE lytB, respectively,      YM-3 filters (Millipore, Eschborn, Germany). flow- derived wild-type E. coli K-12 strain, DSM        lyophilized, resuspended 3 ml H2O  498, ATCC 23716.20,21 mutant wild-type (WT)         analysed high performance layer chromato-
strains harboured plasmid pSC-MVA synthetic              graphy silica gel plates (Kieselgel 60; Merck) developed operon express Saccharomyces cerevisiae ERG12                propanol : ethylacetate : H2O (6 : 1 : 3). Radioactive spots
(mevalonate kinase), ERG8 (phosphomevalonate kinase)            visualized autoradiography exposure                                                                 4 weeks. ERG19 (mevalonate pyrophosphate decarboxylase).20
Bacteria grown Standard 1 medium (Merck,
Darmstadt, Germany) presence 150 mg/ml                cd T-cell stimulation assays
ampicillin (Sigma, Taufkirchen, Germany) 200 mM             Bacteria harvested fresh liquid cultures mevalonate; stock solution 1 M mevalonate              OD600 <0.8 sonicated 1 : 10 volume prepared hydrolysing mevalonolactone (Fluka,                 phosphate-buffered saline (PBS). LMW fractions Taufkirchen, Germany) 1 M KOH 37u 30 min.           obtained using Centriprep 3-kDa filters (Millipore).
                                                                Blood samples healthy donors kindly
Synthesis 14C-labelled MEP                                   provided Institut fu¨r Klinische Immunologie enzymatic synthesis [2-14C]1-deoxy-D-xylulose            und Transfusionsmedizin (Klinikum der Justus-Liebig-
5-phosphate (DOXP), 0.8 mg pyruvate (Sigma), 1.4 mg          Universita¨t Giessen, Giessen, Germany). Peripheral blood [2-14C]pyruvate (585 MBq/mmol; NEN Life Science              mononuclear cells (PBMC) isolated heparinized
Products, Zaventem, Belgium) 5.5 mg D-fructose-          peripheral blood density centrifugation LSM
1,6-bisphosphate (Sigma) incubated 0.44 U rabbit      medium (ICN Biomedicals, Eschwege, Germany). PBMC
aldolase     (D-fructose-1,6-bisphosphate-D-glyceraldehyde-     (2r105  seeded RPMI-1640 (200 ml) supple-
3-phosphate-lyase; Sigma), 22.4 U rabbit triose phosphate       mented 25 mM HEPES, 2 mM L-glutamine, 25 mg/ml


#   2002 Blackwell Science  Immunology, 106, 200–211
 202                                                 M. Eberl et al.


gentamycin  Life Technologies, Karlsruhe,            DgcpE #20, analysed electrospray ionization
Germany) 10  human AB serum (Bayerisches Rotes            orthogonal-time flight mass spectrometry (ESI-o-ToF
Kreuz, Augsburg, Germany). routine assays, recombi-       MS) (Mariner; PE Biosystems, Framingham, MA)
nant human interleukin-2  2) (Life Technologies)       equipped nano-ESI-source (Protana, Odense,
used 10 U/ml short-term cultures (18–72 hr),       Denmark). Sample solutions (3 ml) filled gold- 100 U/ml longer culture periods. comparison        coated nanospray capillaries sprayed flow rates different growth factors, 2, 15            10–30 nl/min. voltage nanospray needle set
Promocell, Heidelberg, Germany), 2125 added         900 V; temperature heated transfer capillary concentration 0.1–10 ng/ml. LMW preparations          200uC. Spectra taken negative ion mode added dilutions 1 200 (corresponding         averaged 10 scans 3 seconds  Structural
<1.0r107 bacteria  1 5r106 (<400 bacteria .   analysis MS-MS selected ions performed
Cells incubated medium  cells stimulated         using quadruple ion trap MS (LCQ; Finnigan MAT, 10 mM IPP (Sigma), served negative positive       San Jose, CA) relative collision energy 20–30 .
controls, repectively. Cells harvested different
time-points analysed cd T-cell activation cd      Statistical analysis
T-cell outgrowth Epics XL flow cytometer sup-           Data expressed mean valuetstandard error ported Expo32 software (Beckman Coulter, Krefeld,        mean (SEM). Statistical analysis performed using
Germany), using following Beckman Coulter                 tailed Student’s t-test unequal variance, monoclonal antibodies (mAbs): CD3-PC5 (UCHT1),                differences considered statistically significant P-value
Vc9-fluorescein isothiocyanate (FITC) (Immu360), Vd2-         <0.05. R2 values calculated using Microsoft Excel
FITC (Immu389), CD25-phycoerythrin (PE) (B1.49.9),            2000 software.
CD69-PE (TP1.55.3), CD94-PE (HP-3B1), HLA-DR-
PE (Immu357), appropriate isotype                                      RESULTS
controls. Gates set total lymphocytes                                                               E. coli DlytB mutants accumulate metabolite CD3+ lymphocytes, results obtained 10 30 000
                                                              derived methyl-D-erythritol
gated events expressed percentage Vc9+ cells CD3+ lymphocytes day 6, CD69+ (day 1),        recent studies, demonstrated enzymes
CD25+ (day 3), CD94+ (day 6), HLA-DR+ (day 6) cells        encoded E. coli genes gcpE lytB essential Vc9+ CD3+ lymphocytes. cytokine analysis,           isoprenoid synthesis MEP pathway.20,21 culture supernatants taken 18 72 hr,           final biochemical steps pathway remain tested tumour necrosis factor (TNF            unveiled, labelling experiments performed order
interferon-c (IFN-c), respectively, using human OptEIA    gain detailed insight function LytB
sets (Becton-Dickinson, Hamburg, Germany).                    GcpE proteins.  DlytB DgcpE mutants                                                               grown medium supplemented 14C-labelled 
Chromatography mass spectrometry                          Separation corresponding LMW extracts 
Cultures DgcpE DlytB mutants, respectively,       layer chromatography revealed DgcpE mutants,
grown 100 ml Standard 1 medium OD600           [2-14C metabolized (Fig. 1). <0.8. LMW extracts prepared described           contrast, DlytB mutant additional
 20 mM ammonium formiate, pH 8.0, used        spot indicating accumulation unknown metabolite
instead PBS) passed Isolute C18 reverse-       reduced chromatographic mobility. Unfortunately, phase (RP) column (International Sorbent Technology,          amounts labelled material limited allow quan-
Mid Glamorgan, UK). flow loaded          tification radioactivity liquid scintillation Source 15Q anion-exchange column (Amersham             characterization mass spectrometry (data shown).
Pharmacia) fractionated using Waters HPLC device
coupled PDA 996 photodiode array detector (Waters,
                                                              Disruption lytB gene leads >100-fold
Eschborn, Germany), scanning 1 spectrum/second                                                               accumulation cd T-cell stimulating molecule
l210 500 nm 1.2-nm resolution. Buffers used   20 mM ammonium formiate, pH 8.0; B, 500 mM           previous work know compound derived
ammonium formiate, pH 8.0; C, 1 M ammonium formiate;          MEP pathway represents natural activator chromatography performed flow rate          phosphoantigen-reactive human cd T cells.3,4  10 ml/min follows: wash, 30 min 100   elution, linear    speculated metabolite accumulating DlytB
gradient 100  100  B 30 min; 10 min 100  C;      bacteria (Fig. 1) fact highly immunogenic
equilibration, 10 min 100   Fractions collected        substance.  cd T-cell stimulation assays, LMW tested standard cd T-cell activation assays     extracts prepared WT bacteria induced expansion dilution 1 400 000, using pools consisting      Vc9/Vd2 T cells dilutions 1 : 12 500, correspond-
fractions  individual fractions pool   ing 1.6r105 bacteria (Fig. 2); accordance inducing upregulation CD69 expression 18 hr         previous observations,4 LMW extracts DgcpE tested dilution 1 400 000. active    mutants active WT E. coli.
sample, DlytB #20, corresponding negative control,     striking contrast, DlytB mutants exhibited


                                                                      #   2002 Blackwell Science  Immunology, 106, 200–211
                                      potent cd T-cell activator DlytB E. coli                                                                                             203

                                                                                          
                                                                                                                   80




                                                                                      Vc9+ [  CD3+ lymphocytes]
                                                                                                                   60


                                                                                                                   40


                                                                                                                   20
              
                                                                                                                    0
                                                                                                                   1E+06          1E+05                1E +04        1E +03
                                                                                                                                       Dilution factor



                                                                      (b)
                                                                                103                                                                  103

                                                                                102                                             2.1                  102                  10.1 




                                                                      CD3-PC5




                                                                                                                                           CD3-PC5
                                                                                101                                                                  101

                                                                                100                                                                  100

                               DgcpE     DlytB
                                                                                                                  100     101    102   103                  100      101   102    103
Figure 1.   layer chromatography analysis Escherichia                                                         Vc9-FITC                                  Vc9-FITC
coli DgcpE DlytB grown presence [2-14C]2-C-methyl-D-              103                                                                  103
erythritol  . Low molecular weight preparations examined HPTLC silica gel plate, radioactive spots visualized             102                                             2.6                  102                 55.8  autoradiography.
                                                                      CD3-PC5




                                                                                                                                           CD3-PC5
                                                                                101                                                                  101

 cd T-cell activity considerably                    100                                                                  100
WT bacteria; significant outgrowth Vc9/Vd2 T cells detected dilutions 1 : 312 500, cor-                                                          100     101    102   103                  100      101   102    103
responding 6.4r103 bacteria  relative increase                                                              Vc9-FITC                                  Vc9-FITC cd T cells detected did reflect true expansion population, substantial death ab T cells occurred            Figure 2. Disruption lytB gene increases cd T-cell
(data shown), accordance similar                 stimulatory potential Escherichia coli.   Vc9+ T-cell outgrowth
observations groups.2,17,26–29                             presence bacterial extracts. Peripheral blood mononuclear
                                                                      cells (PBMC) incubated period 6 days medium
    investigated LMW extracts
                                                                       low molecular weight extracts prepared prepared DlytB bacteria, measuring immunological              wild-type E. coli (black triangles), DgcpE (open circles), parameters correlated cd T-cell activation phospho-           DlytB (open squares), different dilutions. Data shown represent
antigens.  dilution 1 : 62 500, DlytB extract        mean values+standard error mean donors
did stimulate proliferation cd T cells,          analysed. (b) Flow cytometry analysis. PBMC incubated induced upregulation activation markers CD25,                  medium  left panel), LMW extracts prepared
CD69 HLA-DR, C-type lectin CD94                    WT E. coli  right panel), DgcpE  left panel), surface Vc9/Vd2 T cells, secretion TNF             DlytB  right panel), dilution 1 : 12 500. Panels shown
                                                                      representative data obtained blood donor. IFN-c PMBC (Fig. 3). activity present extracts WT DgcpE bacteria tested dilution.                                                             mutant significantly lower, equivalent <0.8 mM.
    Using serial dilutions IPP standard, obtained            Strikingly, LMW extracts bacteria deficient lytB
positive correlations antigen concentration               greater 100-fold active extracts cd T-cell activation, measured cd T-cell expansion                 WT bacteria, containing antigenic compound expression CD25 CD69 (Fig. 4). calibra-              potent <450 mM IPP.
tion curves enabled estimate activity bacterial extracts tested express IPP equivalents;
                                                                      cd T-cell stimulating molecule purified importantly, analyses performed gave similar
                                                                      anion-exchange chromatography
levels (Table 1).  LMW extracts WT E. coli cd T-cell stimulatory potential comparable IPP                order characterize immunogenic molecule
concentration <3 mM, activity DgcpE             accumulating DlytB mutants, 3-kDa LMW filtrate


#   2002 Blackwell Science  Immunology, 106, 200–211
 204                                                                                   M. Eberl et al.

                                                                       CD25                                                                             CD69




                                                                                                CD69+ (  Vc9+ CD3+ lymphocytes)
                   CD25+ (  Vc9+ CD3+ lymphocytes)
                                                     100                                                                            100

                                                     80                                                                             80

                                                     60                                                                             60

                                                     40                                                                             40

                                                     20                                                                             20

                                                      0                                                                              0
                                                           med   IPP    wt     gcpE   lytB                                                med    IPP      wt     gcpE   lytB




                                                                       CD94                                                                             HLA-DR




                                                                                                HLA-DR+ (  Vc9+ CD3+ lymphocytes)
                   CD94+ (  Vc9+ CD3+ lymphocytes)




                                                     100                                                                            100

                                                     80                                                                             80

                                                     60                                                                             60

                                                     40                                                                             40

                                                     20                                                                             20

                                                      0                                                                              0
                                                           med   IPP    wt     gcpE   lytB                                                 med    IPP     wt     gcpE   lytB




                                                                       TNF                                                                             IFN-c
                                                     100                                                                            500

                                                     80                                                                             400
                         TNF (pg/ml)




                                                                                                       IFN-c (pg/ml)




                                                     60                                                                             300

                                                     40                                                                             200

                                                     20                                                                             100

                                                      0                                                                              0
                                                           med   IPP    wt     gcpE   lytB                                                 med    IPP     wt     gcpE   lytB

      Figure 3. Effect DlytB low molecular weight extract range immunological parameters. Peripheral blood
      mononuclear cells (PBMC) incubated medium  isopentenyl pyrophosphate (IPP) 2 mM, LMW
      extract prepared wild-type (WT) Escherichia coli, DgcpE, DlytB, dilution 1 : 62 500. Data represent results       donor, expression CD25 (day 3), CD69 (day 1), CD94 (day 6) human leucocyte antigen (HLA)-DR (day 6)       Vc9+ T cells, secretion tumour necrosis factor (TNF  (day 1) interferon-c (IFN-c) (day 3) PBMC. Note:       pattern shown typical number blood donors analysed (n=3–6);  absolute levels CD94 HLA-DR
      expression, absolute amounts cytokines secreted, greater biological variation individuals       data cd T-cell expansion expression CD25 CD69.  donors changes CD94 HLA-DR
      expression presence serial dilutions phosphoantigens inconsistent despite good dose-dependent responses,       judged CD25 CD69 expression, making CD25 CD69 reproducible activation markers tested.
 passed C18 reversed-phase column                                                pools cd T-cell reactivity. sample obtained fractionated subsequently anion-exchange chromato-                                          DgcpE bacteria stimulated cd T cells background
graphy, using ammonium formiate eluent. LMW                                              levels. contrast, peak bioactivity recovered preparation DgcpE bacteria subjected                                           pool consisting fractions 19–22, samples protocol served control. Unexpectedly,                                     collected, flow column significant difference absorbance profiles                                       wash fractions, remained negative (Fig. 5). Testing DgcpE DlytB mutants, measured                                                  individual fractions positive pool showed 210 500 nm (Fig. 5, data shown).                                           cd T-cell-stimulating molecule eluted fraction  20,
Consequently, fractions collected tested                                      ammonium formiate concentration <250 mM.


                                                                                                                                      #   2002 Blackwell Science  Immunology, 106, 200–211
                                               potent cd T-cell activator DlytB E. coli                                          205

                  10.0                                                 Table 1. Immunological activity extracts different strains
                                                                                            Escherichia coli"

                                                                       Equivalent                    1.0                            R2 =0.997801         IPP (mM)               WT              DgcpE               DlytB
       IPP (µM)




                                                                       Expt. 1{           4.04             0.69             462.58
                                                                       Expt. 2{           2.54             0.85             475.11
                   0.1
                                                                       Expt. 31           2.66             0.79             394.64
                                                                       MeantSEM           3.08t0.48        0.78t0.05*       444.11t25.00*

                   0.0                                                    "Calibration curves obtained using serial dilutions                          0     20      40      60      80        100   isopentenyl pyrophosphate (IPP) standard (Fig. 4). Bioactivity                                 Vc9+ (  CD3+ lymphocytes)              bacterial extracts analysed expressed IPP equivalents                                                                        experiments performed.
                                                                          {Outgrowth Vc9+ CD3+ T cells, day 6 (n=3).
                  10.0                                                    {Upregulation CD25 Vc9+ CD3+ T cells, day 3 (n=3).
                                                                          1Upregulation CD69 Vc9+ CD3+ T cells, day 1 (n=3).
                                                                          *P<0.05, using tailed Student’s t-test unequal variance.
                                                                          SEM, standard error mean; WT, wild type.

                   1.0
       IPP (µM)




                                                R2 =0.944496           derived DlytB bacteria, DlytB #20, cor-
                                                                       responding fraction DgcpE mutants, DgcpE #20.                    0.1                                                 negative ion spectrum DlytB #20, abundant
                                                                       peak m 261 [M-H]x; peaks m 381
                                                                       [M+NaHPO4]x m 523 [2M-H]x correlated
                                                                       molecule (Fig. 6). signals detectable
                   0.0                                                 fraction DgcpE #20, prominent peak
                         0     20      40     60       80        100
                                                                       m 277, common impurity peaks (e.g. m 216.9
                             CD25+ (  Vc9+ CD3+ lymphocytes)
                                                                       m 1192.2) comparable intensities fraction
                                                                       DlytB #20; residual UV absorbance fractions
                  10.0                                                 DlytB #20 DgcpE #20 ascribed ion                                                                        m 1192.2 (data shown). Negative mode ion trap
                               R2 =0.998545                            MS/MS m 261 yielded ions m 243 (correspond-
                   1.0                                                 ing H2O loss) m 159 (corresponding pyro-
                                                                       phosphate anion, HP2Ox    6 ) (data shown). Subsequent
       IPP (µM)




                                                                       large-scale purification cd T-cell activator                                                                        1-l culture E. coli DlytB mutants anion-exchange
                   0.1
                                                                       chromatography, structural characterization                                                                        1
                                                                         H, 13C 31P nuclear magnetic resonance spectros-
                                                                       copy nuclear Overhauser effect spectroscopy anal-
                   0.0                                                 ysis, (E )-4-hydroxy-3-methyl 2-enyl pyrophosphate
                         0     20      40     60       80        100
                                                                       (HMB-PP) described 30
                             CD69+ (  Vc9+ CD3+ lymphocytes)

Figure 4. Dose–response isopentenyl pyrophosphate (IPP).
Peripheral blood mononuclear cells incubated medium          DlytB #20-driven cd T-cell activation does result  IPP different concentrations. data represent     secretion proinflammatory cytokines mean valuetSEM donors analysed, Vc9+ T-cell         presence 21
outgrowth, expression CD25 CD69 Vc9+ T cells.
Trend lines R2 values calculated using Microsoft Excel        Apart reactivity small pyrophosphory-
software.                                                              lated molecules, Vc9/Vd2 T cells depend cytokines                                                                        local microenvironment, fact bias read-
Titration fraction  20 IPP standard gave              outs bioactivity assays. Consequently, investigated bioactivity corresponding <2500 mM IPP (Table 2);                 influence different interleukins cd T-cell fraction  21 <500 mM IPP bioactivity             response novel activator present fraction
(data shown).                                                      DlytB #20. 2 15 clearly impor-
                                                                       tant growth factors known cd T cells,                                                                        synergize 12.26 21 novel cytokine Mass spectrometry analysis identifies molecule Mr 262
                                                                       closely related 2 15, produced activated obtain structural information bioactive metabo-              CD4+ T cells CD19+ B cells CD14+
lite, ESI-MS analysis performed active fraction             monocytes.25  cytokines, 2, 15 

#   2002 Blackwell Science  Immunology, 106, 200–211
 206                                                                                 M. Eberl et al.

                                                                                                                                  80




                                                                                              CD69+ (  Vd2+ CD3+ lymphocytes)
                                                                                                                                                                                                         anion exchange column

                                                                                                                                  60


                                                                                                                                  40


                                                                                                                                  20


                             0.8                                                                                                   0




                                                                                                                                                                                                                       11-14

                                                                                                                                                                                                                                    15-18

                                                                                                                                                                                                                                                 19-22

                                                                                                                                                                                                                                                              23-26

                                                                                                                                                                                                                                                                           27-30

                                                                                                                                                                                                                                                                                   31-35
                                                                                                                                                                                                         wash
                                                                                                                                       medium

                                                                                                                                                 IPP

                                                                                                                                                       LMW



                                                                                                                                                                                               f/t
                                                                                                                                                             RP
                             0.6




                                                                                                                                                             CD69+ (  Vd2+ CD3+ lymphocytes)
                                                                                                                                                                                                80
    Absorbance 280 nm




                                                                                                                                                                                                60
                             0.4
                                                                                                                                                                                                40


                                                                                                                                                                                                20

                             0.2                                                                                                                                                                     0




                                                                                                                                                                                                                               19

                                                                                                                                                                                                                                            20

                                                                                                                                                                                                                                                         21

                                                                                                                                                                                                                                                                      22
                                                                                                                                                                                                                wash
                               0
                                                                          19
                                                                               20
                                                                                    21
                                                                                         22




                           Figure 5. Fractionation bacterial extracts anion-exchange chromatography. DgcpE DlytB low molecular weight
                           (LMW) extracts, respectively, passed reverse phase (RP) column fractionated Source 15Q column, using
                           ammonium formiate gradient (20–500 mM). Absorbance 280 nm shown solid line DlytB dashed line                            DgcpE. Fractions collected tested pools consisting  fractions 19 22 subsequently tested
                           individually ability upregulate CD69 expression Vd2+ T cells. Samples tested  medium control; isopentenyl
                           pyrophosphate (IPP) positive control, 10 mM; 3-kDa LMW filtrate, 1 50 000 (LMW) extract; LMW extract RP
                           column chromatography (=sample loaded Source 15Q column), 1 50 000 (RP); Source 15Q flow  1 50 000
                           (f/t); Source 15Q wash fraction, 1 50 000; fractions 11–35, pools individually, 1 400 000. Solid bars, DgcpE; hatched
                           bars, DlytB.


 21, costimulated expansion Vc9/Vd2 T cells                                                                            maximum 21 induced IFN-c levels lower CD3+ T cells presence fraction DlytB #20,                                                                       achieved presence 2 15. antigen cytokines significant
proliferative effect (Fig. 7).  21 increased DlytB #20-driven upregulation CD25 CD69 Vc9/                                                                                                                                    DISCUSSION
Vd2 T cells, similarly 2 15, effect                                                                    past years, Vc9/Vd2 T cells shown CD25 CD69 expression absence antigenic                                                                         react pathogenic bacteria, Brucella,
stimulation barely detectable, contrast                                                                     Coxiella, Ehrlichia, E. coli, Francisella, Legionella, Listeria,
cytokines tested. Addition 21 PBMC cultures                                                                            Mycobacterium, Pseudomonas, Salmonella Yersinia, enhanced 2- 15-induced upregulation CD69                                                                        protozoan parasites Plasmodium expression, presence absence antigenic                                                                        Toxoplasma.12,31,32 bacteria lacking stimulation; additive effect CD25 expression cd                                                                      alternative MEP pathway isoprenoid synthesis, T-cell proliferation pronounced (data shown).                                                                      Staphylococcus Streptococcus, capable 2 15 costimulated DlytB #20-induced                                                                         stimulating Vc9/Vd2 T cells superantigen recognition
synthesis TNF IFN-c PBMC, 21 did                                                                            sites,33,34 recent studies established general link enhance DlytB #20-driven TNF production,                                                                              Vc9/Vd2 T-cell reactivity35 presence 

                                                                                                                                        #       2002 Blackwell Science  Immunology, 106, 200–211
                                                    potent cd T-cell activator DlytB E. coli                                                                                  207


MEP pathway.3,4 Accordingly, current data                                                                   HLA-DR,36 killer inhibitory receptor, clear LytB enzyme21 plays crucial role                                                               CD94,37 surface Vc9/Vd2 T cells, proliferation
metabolism natural Vc9/Vd2 TCR ligand. Stimula-                                                                     expansion Vc9/Vd2 T cells,4 secretion tion human PBMC minute quantities DlytB                                                                         proinflammatory cytokines IFN-c TNF 27,38,39
LMW preparations led drastic upregulation                                                                          Recently, molecule Mr 262 (TUBag1) identified
known T-cell activation markers CD25,26 CD6926                                                                         Mycobacterium fortuitum. Data ion-trap ESI-MS
                                                                                                                           comparative photodiode array absorption analysis
                                                                                                                           TUBag1, NMR spectroscopy signals       Table 2. Immunological activity fraction DlytB #20*                                                               obtained using corresponding c-UTP c-TTP
                                                                                                                           phosphodiesters, TUBag3 TUBag4, suggested                                  CD69 expression                                Bioactivity
Dilution factor                 (  Vc9+ CD3+){                                  (mM IPP){
                                                                                                                           mycobacterial cd T-cell activator FBPP.13,16,17                                                                                                                            potent natural Vc9/Vd2 T-cell stimulator
Medium control                          29.8t8.4                             –                                             identified date, compound active low nM
6.25r107                                29.9t12.4                            –                                             range, natural synthetic substances
1.25r107                                35.1t7.0                             3759.5                                         IPP prenyl pyrophosphates, alkyl-
2.5r106                                 40.4t1.4                             1823.8
                                                                                                                           phosphates, alkylamines, aminobisphosphonates) 5.0r105                                 52.2t0.2                             2592.5
1.0r105                                 63.0t1.3                             3104.2
                                                                                                                           bioactivities 1 100 mM.13,15,28,29,40– 42 2.0r104                                 66.2t0.6                             1065.9                                         synthetic FBPP derivatives halohydrin
MeantSEM1                               –                                    2469.2t472.7                                  pyrophosphates bioactivities similar  
                                                                                                                           naturally occurring cd T-cell activator,     calibration curve obtained using serial dilutions                                                          described.43– 46  connection FBPP isopentenyl pyrophosphate (IPP) standard, ranging 80 nM
                                                                                                                           MEP pathway isoprenoid synthesis 10 mM yielding formula  R2=0.99): Bioactivity
                          .
(mM IPP)=0.000869re0 167r(CD69 expression level).                                                                          deduced indirectly close structural similarity
   {Upregulation CD69 expression monitored incubation                                                         FBPP IPP.17 mass 262 atomic units peripheral blood mononuclear cells 18 hr presence serial                                                  fragments m 243 m 159, dilutions fraction DlytB #20 (n=3).
                                                                                                                           present study, accordance chemical structure
   {Bioactivity fraction DlytB #20 calculated dilution
using formula: BioactivityDlytB #20 (mM IPP)=(1/1000r[bioactivity                                                      FBPP;17  related molecules 3,4-epoxy-
(mM IPP)rdilution factor]).                                                                                                3-methyl-1-butyl pyrophosphate (EpoxPP),    1Mean bioactivity dilutions tested resulted                                                       identical fragmentation patterns,44 making upregulation CD69 expression background value.                                                                                                                            MS-based approach insufficient support proposed
analogous experiment measuring cd T-cell expansion 6 days
resulted bioactivity value 2487.6t911.4 mM IPP.                                                                    structure.45  recent 1H, 13C 31P NMR spectros-
   SEM, standard error mean.                                                                                        copy studies purified substance identified                                                                  277.0




                          DgcpE

                                        100
                            Intensity




                                         50
                                                  216.9

                                                                     299.0


                                                                              396.9
                                                 133.0




                                                                                                                                                                     1192.2
                                                                                                                  554.9
                                                179.0
                                                 97.0



                                                244.1


                                                                             374.9




                                                                                                                                          771.2
                                                                                                                                  673.2




                                                                                                                                                      854.9




                                            0
                                                                  300                                   550                                800                1050            m                                                                 [M-H]–
                                                                261.0




                          DlytB

                                        100
                                                                              380.9 [M+NaHPO4]–
                            Intensity




                                                                                                  523.0 [2M-H]–




                                         50
                                                                 277.0
                                                        216.9
                                                       158.9




                                                                                                                                                                     1192.2
                                                97.0




                                                                                                                                              806.9
                                                                                                                          642.9




                                            0
                                                                  300                                   550                                800                1050            m 
        Figure 6. Negative mode electrospray ionization-mass spectrometry (ESI-MS) analysis fractions DgcpE #20 DlytB #20.


#   2002 Blackwell Science  Immunology, 106, 200–211
 208                                                                        M. Eberl et al.




      CD69+ (  Vc9+ CD3+ lymphocytes)
                                        100                              100                                100

                                         80                               80                                 80

                                         60                               60                                 60

                                         40                               40                                 40

                                         20                               20                                 20

                                          0                                0                                  0
                                               0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0
      CD25+ (  Vc9+ CD3+ lymphocytes)




                                        100                              100                                100

                                         80                               80                                 80

                                         60                               60                                 60

                                         40                               40                                 40

                                         20                               20                                 20

                                          0                                0                                  0
                                               0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0


                                         30                               30                                 30
      Vc9+ (  CD3+ lymphocytes)




                                         20                               20                                 20



                                         10                               10                                 10



                                          0                                0                                  0
                                               0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0


                                        800                              800                                 800


                                        600                              600                                 600
            TNF (pg/ml)




                                        400                              400                                 400


                                        200                              200                                 200


                                          0                                0                                  0
                                               0   0.1     1.0    10.0          0   0.1    1.0       10.0          0   0.1    1.0   10.0


                                        2500                             2500                               2500

                                        2000                             2000                               2000
            IFN-c (pg/ml)




                                        1500                             1500                               1500

                                        1000                             1000                               1000

                                         500                              500                                500

                                          0                                0                                  0
                                               0    0.1    1.0    10.0          0    0.1     1.0 10.0              0    0.1     1.0 10.0
                                                   2 (ng/ml)                     15 (ng/ml)                      21 (ng/ml)




                                                                                                 #   2002 Blackwell Science  Immunology, 106, 200–211
                                           potent cd T-cell activator DlytB E. coli                                                  209


cd TCR ligand accumulating E. coli DlytB mutants                       eluted anion-exchange column HMB-PP, novel compound derived MEP                          conditions m 261 compound; correspon-
pathway <104 times potent activating Vc9/                 dence chromatographical behaviour result
Vd2 T cells IPP.30 contrast FBPP, chemical                 close chemical similarity metabolites
structure HMB-PP accordance incorporation                   MEP pathway. presence pyrophosphate
studies using deuterium-labelled isotopomers,18                    group m 277 molecule confirmed ion trap
insinuates elegant mechanism unclear                 MS/MS (U. Bahr M. Hintz, unpublished). 
biosynthetic reaction sequence leading MEcPP IPP                  ings suggest E. coli DgcpE overproduc-
(Fig. 8).  present know                  tion MEcPP serve putative substrate
Vc9/Vd2 TCR ligand actual substrate LytB                    GcpE enzyme catalysing synthesis natural
merely represents product MEP pathway,                      cd TCR ligand, precursor.47 conclusion cor-
utilizing intermediate produced GcpE                     roborated recent data indicating MEcPP itself does unidentified enzyme downstream GcpE).                          display cd T-cell activity.48
recently Hecht et al. detected HMB-PP bacteria                        addition molecular characterization overexpressing gcpE gene,47 supporting                   cd T-cell activator, identified 21 potent
conclusions.30                                                            costimulator human phosphoantigen-reactive Vc9/Vd2
    Finally, important note E. coli DgcpE                   T cells. confirms expansion activated cd T cells
mutants accumulate metabolite derived                     depends additional growth factors derive MEP pathway, detectable mass m 277                     bystander CD4+ T cells antigen-specific
                                                                          immune response pathogen, 2, 4                                                                           7, cells innate immune early
                                DOXP
                                                                          stages infection CD4+ T cells                                                                           recruited, like 12 15.26 synergism                                         Dxr                               21 2 15 accordance previous
                                                                          findings showing combinations 21 2
                                 MEP                                      15 additive effect lytic function                                         YgbP                              human natural killer cells;  21 potentiates
                                        YchB                              costimulation murine T-cell proliferation 2
                                        YgbB                              15.25,49 biological implication seemingly
                                                                          redundant utilization 21 Vc9/Vd2 T-cell
                                MEcPP
                                                                          costimulator remains elucidated, 2                                         GcpE                              21 produced activated CD4+ T cells,                                                                           signalling interleukins, 2, 15 21,
                               HMB-PP
                                                                          respective receptors involves activation STAT1,
                          (cd T cell activator)                           STAT3 STAT5, JAK1 JAK3.50,51                                                                           respect, intriguing 21 similar effects                                         LytB                              2 15 DlytB #20-driven cd T-cell pro-
                                                                          liferation CD25 CD69 surface expression,                                   IPP                                     far active stimulating DlytB #20-induced
                                                                          secretion IFN-c TNF PBMC. findings
Figure 8. Proposed scheme final biosynthetic reactions
                                                                          demonstrate production proinflammatory 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway Escherichia coli. Initially, 1-deoxy-D-xylulose 5-phosphate (DOXP)        cytokines, considered key function converted MEP DOXP reductoisomerase (Dxr).                     Vc9/Vd2 T cells widely used read bio-
Subsequently, enzymes YgbP, YchB YgbB catalyse                activity assays,27,38,39 necessarily associated transformation MEP 2-C-methyl-D-erythritol 2,4-cyclo-             proliferating Vc9/Vd2 T cells. immunology 21
pyrophosphate (MEcPP), molecular mass (Mr) 278.                 costimulated phosphoantigen-reactive Vc9/Vd2 T cells GcpE involved step(s) using MEcPP substrate          worth attention.
produce cd T-cell activator, (E )-4-hydroxy-3-methyl 2-enyl           Taken  demonstrated pyrophos-
pyrophosphate (HMB-PP) Mr 262, LytB mediates
                                                                          phorylated molecule Mr 262 accounts strong subsequent reaction leading IPP.
                                                                          immunogenicity mutant E. coli strain deficient lytB.


        Figure 7. Dependence cd T-cell activity costimulation interleukin  -2, 15 21. Peripheral blood
        mononuclear cells incubated medium (open circles), DlytB #20 dilution 1 100 000,
        corresponding bioactivity equivalent 25 mM isopentenyl pyrophosphate (IPP) (solid circles), presence different
        concentrations recombinant cytokines. Data shown represent mean value+SEM expression CD69 CD25
        Vc9+ CD3+ T cells, outgrowth Vc9+ T cells CD3+ T cells, secretion interferon-c (IFN-c)         tumour necrosis factor (TNF   n=6 n=3 IFN-c). *P<0.05 compared corresponding medium
        controls, using tailed Student’s t-test paired data.


#   2002 Blackwell Science  Immunology, 106, 200–211
 210                                                          M. Eberl et al.

 increasing evidence Vc9/Vd2 T cells                    11 Eisenreich W, Rohdich F, Bacher  Deoxyxylulose phosphate
contribute immune response                      pathway terpenoids. Trends Plant Sci 2001; 6:78–84. harmful pathogens infecting humans, unexpected                 12 Sicard H, Fournie´ JJ. Metabolic routes targets accessibility natural Vc9/Vd2 TCR ligand large                   immunological discrimination host parasite. Infect
                                                                           Immun 2000; 68:4375–7.
quantities, identification 21 potent growth
                                                                        13 Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G,
factor, aid understanding unconven-
                                                                           Bonneville M, Fournie´ JJ. Stimulation human cd T cells tional function Vc9/Vd2 T cells diseases                     nonpeptidic mycobacterial ligands. Science 1994; 264:267–70.
tuberculosis, tularemia, malaria, Crohn’s disease.52–55              14 Tanaka Y, Sano S, Nieves E et al. Nonpeptide ligands fact presence 21, DlytB #20-reactive                 human cd T cells. Proc Natl Acad Sci USA 1994; 91:8175–9.
Vc9/Vd2 T-cells proliferate secreting significant               15 Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB,
levels proinflammatory cytokines consider-                    Bloom BR. Natural synthetic non-peptide antigens
able relevance immunotherapeutic approaches                   recognized human cd T cells. Nature 1995; 375:155–8.
infections.                                                             16 Poquet Y, Constant P, Halary F et al. novel nucleotide-
                                                                           containing antigen human blood cd T lymphocytes. Eur
                                                                           J Immunol 1996; 26:2344 –9.
                   ACKNOWLEDGMENTS                                      17 Belmant C, Espinosa E, Poupot R, Peyrat MA, Guiraud M, study supported Bundesministerium fu¨r Bildung             Poquet Y, Bonneville M, Fournie´ JJ. 3-Formyl-1-butyl
und Forschung (BioChance 0312588), studentship               pyrophosphate: novel mycobacterial metabolite-activating Deutsche Forschungsgemeinschaft  K.K). gratefully              human cd T cells. J Biol Chem 1999; 274:32079–84.
acknowledge Rosel Engel, Christian Haug, Dajana Henschker,              18 Charon L, Hoeffler JF, Pale-Grosdemange C, Lois LM,
Ursula Jost, Irina Steinbrecher, Stefanie Wagner excellent         Campos N, Boronat  Rohmer M. Deuterium-labelled
technical assistance; Erhard Dreiseidler, Claus Weidemeyer,            isotopomers 2-C-methyl-D-erythritol tools elucida- Oliver Wolf helpful discussions.                                   tion 2-C-methyl-D-erythritol 4-phosphate pathway                                                                            isoprenoid biosynthesis. Biochem J 2000; 346:737– 42.
                                                                        19 Takahashi S, Kuzuyama T, Watanabe H, Seto H. 1-deoxy-
                         REFERENCES                                        D-xylulose 5-phosphate reductoisomerase catalyzing forma-
                                                                           tion 2-C-methyl-D-erythritol 4-phosphate alternative
 1 Goerlich R, Hacker G, Pfeffer K, Heeg K, Wagner H.
                                                                           nonmevalonate pathway terpenoid biosynthesis. Proc Natl
   Plasmodium falciparum merozoites primarily stimulate                                                                            Acad Sci USA 1998; 95:9879–84.
   Vc9 subset human c/d T cells. Eur J Immunol 1991;
                                                                        20 Altincicek B, Kollas AK, Sanderbrand S, Wiesner J, Hintz M,
   21:2613–6.
                                                                           Beck E, Jomaa H. GcpE involved 2-C-methyl-D-
 2 Kabelitz D, Bender  Schondelmaier S, Schoel B,
                                                                           erythritol 4-phosphate pathway isoprenoid biosynthesis    Kaufmann SH. large fraction human peripheral blood
                                                                           Escherichia coli. J Bacteriol 2001; 183:2411–6.
   c/d+ T cells activated Mycobacterium tuberculosis                                                                         21 Altincicek B, Kollas AK, Eberl M, Wiesner J, Sanderbrand S,
   65-kDa heat shock protein. J Exp Med 1990; 171:667–75.
                                                                           Hintz M, Beck E, Jomaa H. LytB, novel gene 2-C-
 3 Jomaa H, Feurle J, Luhs K, Kunzmann V, Tony HP,
   Herderich M, Wilhelm M. Vc9/Vd2 T cell activation induced               methyl-D-erythritol 4-phosphate pathway isoprenoid
   bacterial low molecular mass compounds depends                    biosynthesis Escherichia coli. FEBS Lett 2001; 499:37– 40.
   1-deoxy-D-xylulose 5-phosphate pathway isoprenoid             22 Cunningham FX Jr, Lafond TP, Gantt E. Evidence role    biosynthesis. FEMS Immunol Med Microbiol 1999; 25:371–8.                LytB nonmevalonate pathway isoprenoid biosynthesis.
 4 Altincicek B, Moll J, Campos N et al. Human cd T cells              J Bacteriol 2000; 182:5841–8.
   activated intermediates 2-C-methyl-D-erythritol            23 Campos N, Rodrı´guez-Concepcio´n M, Seemann M, Rohmer M,
   4-phosphate pathway isoprenoid biosynthesis. J Immunol               Boronat  Identification gcpE novel gene 2-C-
   2001; 166:3655–8.                                                       methyl-D-erythritol 4-phosphate pathway isoprenoid bio-
 5 Rohmer M, Knani M, Simonin P, Sutter B, Sahm H. Isoprenoid              synthesis Escherichia coli. FEBS Lett 2001; 488:170 –3.
   biosynthesis bacteria: novel pathway early              24 Altincicek B, Hintz M, Sanderbrand S, Wiesner J, Beck E,
   steps leading isopentenyl diphosphate. Biochem J 1993;               Jomaa H. Tools discovery inhibitors 1-deoxy-D-
   295:517–24.                                                             xylulose 5-phosphate (DXP) synthase DXP reducto-
 6 Rosa Putra S, Disch  Bravo JM, Rohmer M. Distribution              isomerase: approach enzymes pathogenic
   mevalonate glyceraldehyde 3-phosphate/pyruvate routes               bacterium Pseudomonas aeruginosa. FEMS Microbiol Lett
   isoprenoid biosynthesis Gram-negative bacteria          2000; 190:329–33.
   mycobacteria. FEMS Microbiol Lett 1998; 164:169–75.                  25 Parrish-Novak J, Dillon SR, Nelson et al. Interleukin 21  7 Jomaa H, Wiesner J, Sanderbrand S et al. Inhibitors                  receptor involved NK cell expansion regulation
   nonmevalonate pathway isoprenoid biosynthesis                 lymphocyte function. Nature 2001; 408:57–63.
   antimalarial drugs. Science 1999; 285:1573–6.                        26 Wesch D, Marx S, Kabelitz D. Comparative analysis ab
 8 Rohmer M. discovery mevalonate-independent path-               cd T cell activation Mycobacterium tuberculosis    way isoprenoid synthesis bacteria, algae higher plants.      isopentenyl pyrophosphate. Eur J Immunol 1997; 27:952–6.
   Nat Prod Rep 1999; 16:565–74.                                        27 Garcı VE, Sieling PA, Gong J et al. Single-cell cytokine
 9 Lange BM, Rujan T, Martin W, Croteau R. Isoprenoid                      analysis cd T cell responses nonpeptide mycobacterial
   biosynthesis: evolution ancient distinct pathways        antigens. J Immunol 1997; 159:1328–35.
   genomes. Proc Natl Acad Sci USA 2000; 97:13172–7.             28 Bukowski JF, Morita CT, Brenner MB. Human cd T cells
10 Boucher Y, Doolittle WF. role lateral gene transfer       recognize alkylamines derived microbes, edible plants,
   evolution isoprenoid biosynthesis pathways. Mol Microbiol            tea: implications innate immunity. Immunity 1999;
   2000; 37:703–16.                                                        11:57–65.


                                                                                #   2002 Blackwell Science  Immunology, 106, 200–211
                                      potent cd T-cell activator DlytB E. coli                                                 211

29 Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP,              42 Espinosa E, Belmant C, Sicard H, Poupot R, Bonneville M,
   Wilhelm M. Stimulation cd T cells aminobisphosphonates          Fournie´ JJ. Y2K+1 state art non-peptide phospho-
   induction antiplasma cell activity multiple myeloma.        antigens, novel category immunostimulatory molecules.
   Blood 2000; 96:384 –92.                                               Microbes Infect 2001; 3:645–54.
30 Hintz M, Reichenberg  Altincicek B et al. Identification      43 Belmant C, Espinosa E, Halary F et al. chemical basis    (E )-4-hydroxy-3-methyl 2-enyl pyrophosphate major           selective recognition nonpeptide antigens human cd T cells.
   activator human cd T cells Escherichia coli. FEBS Lett         FASEB J 2000; 14:1669–70.
   2001; 509:317–22.                                                  44 Pont F, Luciani B, Belmant C, Fournie´ JJ. Characterization
31 Kaufmann SH. c/d unconventional T lymphocytes:              phosphoantigens high-performance anion-exchange
    Proc Natl Acad Sci USA          chromatography-electrospray ionization ion trap mass
   1996; 93:2272–9.                                                      spectrometry nanoelectrospray ionization ion trap mass
32 Kabelitz D, Glatzel  Wesch D. Antigen recognition                spectrometry. Anal Chem 2001; 73:3562–9.
   human cd T lymphocytes. Int Arch Allergy Immunol 2000;             45 Feurle J, Espinosa E, Eckstein S et al. E. coli produces
   122:1–7.                                                              phosphoantigens activating human cd T cells. J Biol Chem 2002;
33 Munk  Gatrill AJ, Kaufmann SH. Target cell lysis 2          277:148–54.
   secretion c/d T lymphocytes activation bacteria.     46 Espinosa E, Belmant C, Pont F et al. Chemical synthesis
   J Immunol 1990; 145:2434 –9.                                          biological activity bromohydrin pyrophosphate, 34 Morita CT, Li H, Lamphear JG, Rich RR, Fraser JD,                     potent stimulator human cd T cells. J Biol Chem 2001;
   Mariuzza RA, Lee HK. Superantigen recognition cd
                                                                         276:18337– 44.
   T cells: SEA recognition site human Vc2 T cell receptors.
                                                                      47 Hecht S, Eisenreich W, Adam P et al. Studies    Immunity 2001; 14:331– 44.
                                                                         nonmevalonate pathway terpenes: role GcpE
35 Allison TJ, Winter CC, Fournie´ JJ, Bonneville M, Garboczi DN.
                                                                         (IspG) protein. Proc Natl Acad Sci USA 2001; 98:14837– 42.
   Structure human cd T-cell antigen receptor. Nature 2001;
                                                                      48 Potapov VD, Biketov SF, Demina GR, Lysak EI, Titareva GM,
   411:820 – 4.
                                                                         Bakhteeva IV, Ostrovsky DN. Immunomodulatory properties
36 Borsellino G, Poccia F, Placido R et al. Phenotypic                                                                          2-C-methyl-D-erythritol 2,4-cyclopyrophosphate    functional properties cd T cells patients Guillain
                                                                         search new derivatives. Appl Biochem Microbiol 2001;
   Barre´ syndrome. J Neuroimmunol 2000; 102:199–207.
37 Boullier S, Poquet Y, Halary F, Bonneville M, Fournie JJ,             37:238– 41.
   Gougeon ML. Phosphoantigen activation induces surface              49 Voßhenrich CA, di Santo JP. Cytokines: 21 joins    translocation intracellular CD94/NKG2A class receptor            cc-dependent network? Curr Biol 2001; 11:R175–7.
   CD94x peripheral Vc9Vd2 T cells CD94x thymic         50 Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ.
   mature cd T cell clones. Eur J Immunol 1998; 28:3399– 410.         Cloning type cytokine receptor related 2
38 Sireci G, Champagne E, Fournie´ JJ, Dieli F, Salerno  Patterns      receptor beta chain. Proc Natl Acad Sci USA 2000;
   phosphoantigen stimulation human Vc9/Vd2 T cell clones          97:11439– 44.
   include Th0 cytokines. Hum Immunol 1997; 58:70 –82.                51 Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D,
39 Lafont V, Liautard J, Liautard JP, Favero J. Production            Sugamura K. Th